Magenta therapeutics inc - made strategic decision to discontinue enrollment in phase 2 study of mgta-456 in inherited metabolic disorders

Magenta therapeutics provides portfolio update: stem cell mobilization and conditioning programs prioritized and advancing toward clinical milestones.magenta therapeutics inc - mgta-145 first-line mobilization program to move into phase 2 studies in autologous and allogeneic patients in 2020.magenta therapeutics inc - mgta-117 antibody-drug conjugate (adc)-based conditioning program on track for initial clinical data in 2021.magenta therapeutics inc - made strategic decision to discontinue enrollment in phase 2 study of mgta-456 in inherited metabolic disorders.magenta therapeutics inc - enrollment in phase 2 investigator-initiated trial in patients with blood cancers is expected to be completed.magenta therapeutics inc - to discontinue enrollment in phase 2 study in imds due to enrollment challenges, particularly during covid-19 pandemic.magenta therapeutics - to discontinue enrollment in phase 2 study in imds, due to challenges of allogeneic stem cell transplant in imds patients.magenta therapeutics - to discontinue enrollment in phase 2 study in imds, also due to feedback from fda on endpoints and clinical trial design.
DNTH Ratings Summary
DNTH Quant Ranking